Prepping for a PrEP Trial (July/August 2009)
Why is it so hard to find young people to participate in HIV-related studies? While trying to find an assistant to help recruit young, gay men for a trial of pre-exposure HIV prophylaxis (PrEP), HIV advocate Keith Green may have stumbled on an answer: homophobia.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Protect Yourselves, Ladies (July/August 2009)
Too many women still believe that HIV is a "gay disease," says Enid V´zquez, a staff member for the Chicago HIV/AIDS organization Test Positive Aware Network (TPAN). But it's not just ignorance about HIV that lies behind the growing number of HIV-positive women in the U.S. (especially among African Americans); it's also a matter of empowerment and personal responsibility.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Boosted Darunavir Monotherapy Works Well in Two Studies (July 23, 2009)
Ritonavir-boosted darunavir alone maintains HIV suppression in most patients who achieved an undetectable viral load on combination antiretroviral therapy, according to two studies.
From aidsmap.com
HIV's Silent Dangers Make Early HIV Treatment Critical, Expert Says (July 21, 2009)
A discussion about inflammation, early treatment and universal treatment access -- Wafaa El-Sadr, M.D., M.P.H., United States.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
African Americans, Women Have Lower Virologic Response Rates in Both Arms of Head-to-Head Antiretroviral Trial (July 20, 2009)
Race and gender may prove to be a more critical factor than we think in virologic response to HIV medications. In the large HEAT study, which compared two first-line HAART regimens, Kimberly Smith, M.D., M.P.H., et al found that in both study arms, fewer African Americans (versus white patients) and females (versus males) achieved a viral load of less than 50 copies/mL.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
HIV Treatment as Prevention: How Many Lives Could Be Saved? (July 20, 2009)
If every person in sub-Saharan Africa received voluntary, annual HIV testing and started antiretroviral therapy immediately after diagnosis, HIV incidence would drop 95% in 10 years and more than seven million deaths would be averted, according to a theoretical model presented by Reuben Granich, M.D., M.P.H.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
If We Can't Overcome HIV Stigma and Discrimination, Access to Care Won't Improve in Africa, Advocate Says (July 20, 2009)
"Right now, we're standing in a sinkhole, with regards to HIV and TB [tuberculosis] treatment" in Africa, said HIV/AIDS advocate Paula Akugizibwe in an eloquent, passionate speech at IAS 2009. "Until we do some serious work, and invest money and time on creating human rights sensitization ... and the imperative of governments to fund this right, then everything else we're doing is essentially self-defeating."
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
"We're Not Doing Enough," Say Global Leaders on HIV as IAS 2009 Opens (July 19, 2009)
In a wide-ranging, impassioned press conference at the opening of IAS 2009, Hoosen Coovadia, M.D., Vuyiseka Dubula, Stephen Lewis and Julio Montaner, M.D., discuss some of the overarching themes and priorities of this year's conference, many of which focus on a desperate need to renew attention (and funding) to the precarious state of efforts to prevent and treat HIV in resource-poor countries.
In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO